First-line treatment of ovarian cancer: questions and controversies to address

by Jonathan A. Ledermann
Published 2018-04-01

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer

by Jonathan A. Ledermann, Eric Pujade-Lauraine
Published 2019-05-01

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

by Daniela Luvero, Andrea Milani, Jonathan A. Ledermann
Published 2014-09-01

ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies

by Jonathan A Ledermann, Ilaria Betella, Maria Del Grande, Francesco Multinu, Cristiana Sessa, Ilaria Colombo, Eleonora Zaccarelli, Federica Tomao, Antonio Gonzalez-Martin
Published 2020-11-01

Self-supervised deep learning for highly efficient spatial immunophenotypingResearch in context

by Hanyun Zhang, Khalid AbdulJabbar, Tami Grunewald, Ayse U. Akarca, Yeman Hagos, Faranak Sobhani, Catherine S.Y. Lecat, Dominic Patel, Lydia Lee, Manuel Rodriguez-Justo, Kwee Yong, Jonathan A. Ledermann, John Le Quesne, E. Shelley Hwang, Teresa Marafioti, Yinyin Yuan
Published 2023-09-01

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease...

by Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman
Published 2021-10-01